Descripción de la empresa
Park Ha Biological Technology Co., Ltd. operates primarily as an investment holding company focused on the research and development of skincare products within the People's Republic of China. The enterprise functions within the Consumer Defensive sector, specifically categorized under the Household & Personal Products industry, which typically implies a demand for goods that remains relatively stable regardless of economic cycles. The company employs a workforce of 41 individuals to support its operations across two distinct segments: Product Sales and Franchise Service. With a market capitalization of $3.28M and annual revenue of $2.52M, the firm presents itself as a micro-cap entity with limited scale, indicating a niche position in the broader market rather than a dominant player in the skincare sector.
Salud financiera
The company reported a revenue of $2.52M over the trailing twelve months, yet this generated a net income of $-24,364,752, highlighting a severe structural disconnect where operating expenses vastly exceeded all income streams. The EBITDA figure stands at $-24,039,532, further confirming that the business is currently operating at a significant loss before interest, taxes, depreciation, and amortization. Free cash flow is negative at $-14,219,369, which indicates that the company is consuming cash reserves rather than generating liquidity to fund operations or capital expenditures. Gross margin is reported at 94.4%, suggesting a high pricing power or low cost of goods sold for the products sold, yet this does not offset the massive operating inefficiencies. In contrast, the operating margin is -344.8% and the profit margin is 0.0%, illustrating that the company burns a disproportionate amount of revenue on overhead costs, resulting in no net profit. On the liquidity side, the firm holds $3.79M in cash against a debt obligation of $180,169, resulting in a debt-to-equity ratio of 4.51, which suggests a highly leveraged capital structure relative to shareholder equity despite the low absolute debt figure. The current ratio of 2.92 implies that the company possesses sufficient current assets to cover its current liabilities nearly three times over, pointing to adequate short-term liquidity despite the operational losses. Return on Equity is -885.8% and Return on Assets is -334.1%, metrics that reveal management is currently ineffective at generating returns on the capital invested by shareholders or deployed in assets.
Evaluación de valoración
The trailing twelve-month P/E ratio and forward P/E ratio are both listed as N/A, a valuation metric implication that arises because the company reports a net loss, rendering traditional earnings-based multiples inapplicable for comparison with profitable peers. The price-to-book ratio is 0.17, indicating that the market values the company's equity at a fraction of its net asset value, which often signals undervaluation or significant concerns regarding the quality of assets. The price-to-sales ratio stands at 1.30, while the EV/EBITDA is 0.12; these alternative metrics suggest that the stock is priced relative to its sales volume given the absence of earnings, though the extremely low EV/EBITDA reflects the negative earnings multiple inherent in a loss-making entity. The 52-week high is $2074.50 and the 52-week low is $0.93, a range so wide it suggests extreme volatility and potential data anomalies or delisting concerns for a security trading at such disparate levels. Without a specific current share price provided in the source facts to calculate the exact percentage below the high, the wide spread between the high and low underscores the speculative nature of the security's price action relative to the broader market. The beta value is N/A, meaning that the historical volatility of the stock price relative to the broader market index cannot be quantified with the available data.
Growth & Income
Revenue growth year-over-year is -15.9%, while earnings growth is N/A due to the company's consistent net losses, indicating that the business is shrinking in terms of top-line sales rather than expanding. Since the earnings growth rate is not available due to negative earnings, it is impossible to determine if earnings are growing faster or slower than revenue, but the contraction in revenue suggests a challenging operating environment for the franchise and product segments. The company does not pay dividends, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means that all available earnings are theoretically retained, though in this case, the firm is burning cash rather than reinvesting profits. The overall growth and income profile is characterized by negative revenue expansion and an absence of shareholder returns through dividends, painting a picture of a company in a difficult financial transition or distress phase.